Switzerland / 5 Trends in Swiss Biotech
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
Primex Pharmaceuticals is an innovative and fast-growing company spearheading a new pharmaceutical business model, in operation since early 2008. It is headquartered in Finland and Switzerland and has a global reach through regional marketing and distribution.
Primex supplies high-quality medicines to healthcare institutions and professionals around the world, from the EU to Asia, and from Latin America to the Middle East. Primex products are available in a total of 39 countries world-wide, while its distribution reaches a population of nearly one billion people.
There are unique medicines for hospital use and specialty practices, all are manufactured in the EU under the strictest quality controls. At present, Primex is specialized in anesthesia,cardiology, oncology and intensive care, and constantly expanding.
Primex is committed to building a profitable long-term business with its affiliates and partners. The Primex Alliance Network, connecting leading regional businesses and deep market knowledge, creates irreplaceable value and forms a strong base for the future of the whole network in all parts of the world. The leading pharmaceutical companies – in countries like Indonesia, Mexico and Saudi Arabia – form the base of Primex’s global success via regional excellence.
Contact
export@primexpharma.com
General Inquiries: +358 503 002 388
Business Development: +41 796 162 694
Export: +41 796 162 444
Primex Pharmaceuticals AG
Obmoos 4
CH-6300 Zug
Switzerland
Primex Pharmaceuticals Ltd
Eteläesplanadi 24 A
FI-00130 Helsinki
Finland
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over…
Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its…
After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment…
Lonza’s global head of Mammalian Biologics, Jennifer Cannon, talks about disruption in the CDMO industry, explains how the Swiss giant is reimagining new models based on risk-sharing, and goes through…
See our Cookie Privacy Policy Here
